[Cytoprotection in Cardiology: Achievements and Prospects]. 2015

V P Mikhin
Department of Internal Medicine 2 Kursk State Medical University Ministry of Health of the Russian Federation, Kursk, Russia.

Currently, pharmacotherapy of coronary heart disease, based on antianginal drugs directly improve coronary blood flow, antiplatelet, and lipid-lowering drugs, includes a new class of drugs - cardiocytoprotectors. Recent ischemic cardiomyocytes improve security in the ATP, by optimizing the energy metabolism by reducing the need for oxygen cardiomyocytes and has an antioxidant effect, protecting cellular structures and enzymes from oxidative stress accompanying hypoxia.

UI MeSH Term Description Entries

Related Publications

V P Mikhin
August 1985, Immunology today,
V P Mikhin
March 1978, Science (New York, N.Y.),
V P Mikhin
January 1992, Irish medical journal,
V P Mikhin
January 1977, Terapevticheskii arkhiv,
V P Mikhin
December 1982, Meditsinskaia sestra,
V P Mikhin
January 1992, Klinicheskaia meditsina,
V P Mikhin
January 1973, Przeglad lekarski,
V P Mikhin
January 1965, La Sante publique,
Copied contents to your clipboard!